TGS Baltic has successfully represented the shareholders of the AS Grindeks pharmaceutical company in Latvia's appellate court against a EUR 1,903,294.80 damages claim by VAS Privatizacijas Agentura arising from Grindeks' failure to make an allegedly mandatory buy-back offer.
TGS Baltic’s team consisted of Partners Ivars Grunte and Nauris Grigals.
According to TGS Baltic, the appellate court's ruling remains subject to "appeal in the high court senate."
